Klotho Neurosciences Declares Letter of Intent No Longer Valid

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Oct 07 2025

0mins

KLTO+8.61%

Should l Buy KLTO?

Source: Newsfilter

Klotho's Strategic Decision: Klotho Neurosciences, Inc. has allowed its Letter of Intent with Turn Biotechnologies to expire, as the proposed transaction did not align with the company's long-term strategic goals. The company will instead focus on advancing its anti-aging protein research and treatment development.
Market Context and Focus: The longevity medicine market is rapidly growing, driven by an aging global population expected to reach 2.1 billion by 2050. Klotho's research is centered on the human Klotho protein, which is crucial for longevity and aims to address neurodegenerative and age-related disorders.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy KLTO?" and start using high-conviction signals backed by rigorous historical data.

KLTO

$0.2402+Infinity%1D

Analyst Views on KLTO

About KLTO

Klotho Neurosciences, Inc. develops essential medicines for the treatment of chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The Company's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The Company's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Klotho CEO Dr. Joseph Sinkule to Present at Biotech Showcase on January 13, 2026

Jan 08 2026Newsfilter

Showcase Participation: Klotho Neurosciences, Inc. CEO Dr. Joseph Sinkule will present at the Biotech Showcase on January 13, 2026, at 11:30 AM PT in San Francisco, highlighting the company's innovations in biogenetics.
Investor Meetings: The company will hold one-on-one meetings with investors and potential partners during the event, aiming to strengthen connections with key stakeholders in the industry and drive future collaboration opportunities.
Technological Focus: Klotho specializes in developing cell and gene therapies based on the human Klotho gene, aiming to improve treatments for neurodegenerative diseases, showcasing its technological potential in the biopharmaceutical sector.
Market Outlook: This event provides Klotho with an opportunity to showcase its innovative therapies, potentially attracting investor interest and laying the groundwork for the company's future commercial operations.

Coinbase CEO Armstrong Invests in NewLimit, Secures $45 Million Funding

Jan 06 2026Benzinga

Company Formation: Coinbase CEO Brian Armstrong's startup NewLimit, founded in 2021, focuses on extending human healthspan by treating age-related diseases, with its latest funding round of $45 million boosting its valuation to $1.62 billion, indicating strong market interest in anti-aging technologies.
Funding Context: The rapid follow-up funding just five months after its Series B round demonstrates NewLimit's swift growth and investor confidence in the anti-aging sector, with the new capital expected to lay the groundwork for future clinical studies that could advance its technological capabilities.
Intensifying Competition: With OpenAI CEO Sam Altman investing $180 million in Retro Biosciences, the race to develop technologies that extend human lifespan is heating up, reflecting significant market attention and potential economic returns in this burgeoning field.
Market Reaction: Despite a downturn in anti-aging research stocks in 2025, NewLimit's successful funding round showcases investor confidence in its long-term potential, which may attract further capital into this emerging market.

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Nov 07 2025PRnewswire

Award Recognition: Klotho Neurosciences, Inc. has won the Fifth Annual BioTech Breakthrough Award for "Cell Therapy Innovation of the Year" for its groundbreaking work in gene and cell therapies targeting neurodegenerative diseases.
Innovative Therapies: The company focuses on using a patented form of the human Klotho gene (s-KL) to develop therapies aimed at slowing or reversing diseases like ALS, Alzheimer's, and Parkinson's, addressing the root causes of neuronal aging.
Commitment to Patients: CEO Dr. Joseph Sinkule emphasized the importance of developing therapies that improve health span and reduce the burden of age-related diseases, especially as the global population ages.
BioTech Breakthrough Awards: The awards program recognizes innovative companies and technologies in the life sciences and biotechnology sectors, celebrating excellence in various fields including biopharma and therapeutics.

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Oct 16 2025PRnewswire

Klotho Neurosciences at Longevity Biotech 2025: Klotho Neurosciences, Inc. will participate in the Longevity Biotech 2025 conference in Boston on October 22-23, 2025, engaging with investors and potential partners to discuss advancements in longevity therapeutics.
Company Focus and Innovations: The company specializes in developing disease-modifying cell and gene therapies targeting neurodegenerative and age-related disorders, utilizing a patented form of the "anti-aging" Klotho gene and innovative delivery systems.